HK1148667A1 - Mequitazine for treating or preventing pathologies involving histamine h4 receptors - Google Patents

Mequitazine for treating or preventing pathologies involving histamine h4 receptors

Info

Publication number
HK1148667A1
HK1148667A1 HK11102709.5A HK11102709A HK1148667A1 HK 1148667 A1 HK1148667 A1 HK 1148667A1 HK 11102709 A HK11102709 A HK 11102709A HK 1148667 A1 HK1148667 A1 HK 1148667A1
Authority
HK
Hong Kong
Prior art keywords
mequitazine
receptors
treating
pathologies involving
phenothiazine
Prior art date
Application number
HK11102709.5A
Other languages
English (en)
Inventor
Thierry Clerc
Christophe Przybylski
Jacky Tisne-Versailles
Didier Cussac
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of HK1148667A1 publication Critical patent/HK1148667A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK11102709.5A 2007-12-04 2011-03-18 Mequitazine for treating or preventing pathologies involving histamine h4 receptors HK1148667A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0759538A FR2924344B1 (fr) 2007-12-04 2007-12-04 Utilisation de la mequitazine sous la forme de racemate ou d'enantiomeres pour la preparation d'un medicament destine au traitement ou a la prevention de pathologies impliquant les recepteurs histaminiques h4.
FR0854144A FR2924345B1 (fr) 2007-12-04 2008-06-23 Utilisation de la mequitazine sous la forme de racemate ou d'enantiomeres pour la preparation d'un medicament destine au traitement ou a la prevention de pathologies impliquant les recepteurs histaminiques h4.
PCT/EP2008/066787 WO2009071625A1 (fr) 2007-12-04 2008-12-04 Utilisation de méquitazine sous sa forme racémate ou énantiomère dans la préparation d'un médicament destiné à traiter ou à prévenir les pathologies impliquant les récepteurs h4 de l'histamine

Publications (1)

Publication Number Publication Date
HK1148667A1 true HK1148667A1 (en) 2011-09-16

Family

ID=39522380

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11102709.5A HK1148667A1 (en) 2007-12-04 2011-03-18 Mequitazine for treating or preventing pathologies involving histamine h4 receptors

Country Status (22)

Country Link
US (1) US20100273752A1 (fr)
EP (2) EP2255811A1 (fr)
JP (2) JP2011505411A (fr)
KR (1) KR20100108347A (fr)
CN (1) CN101883566B (fr)
AR (1) AR070673A1 (fr)
AU (1) AU2008333220B2 (fr)
BR (1) BRPI0820652A2 (fr)
CA (1) CA2706898A1 (fr)
CL (1) CL2008003584A1 (fr)
FR (2) FR2924344B1 (fr)
HK (1) HK1148667A1 (fr)
IL (1) IL206073A0 (fr)
MA (1) MA31930B1 (fr)
MX (1) MX2010006139A (fr)
NZ (1) NZ586212A (fr)
PA (1) PA8805501A1 (fr)
RU (1) RU2510273C2 (fr)
TN (1) TN2010000241A1 (fr)
TW (1) TW200932242A (fr)
WO (1) WO2009071625A1 (fr)
ZA (2) ZA201004312B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2201982A1 (fr) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur H4 de l'histamine pour le traitement de troubles vestibulaires
EP2858647B1 (fr) 2012-06-08 2018-05-23 Sensorion Inhibiteurs du récepteur h4 pour le traitement du tinnitus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2440371A1 (fr) * 1978-10-31 1980-05-30 Fisons Ltd Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer
FR2522660A1 (fr) * 1982-03-05 1983-09-09 Pharmuka Lab Isomere levogyre de la mequitazine, son procede de preparation et medicaments le contenant
JPS6330420A (ja) * 1986-07-25 1988-02-09 Sekisui Chem Co Ltd 持続性抗アレルギ−固形塗布剤
JP2735122B2 (ja) * 1988-06-13 1998-04-02 旭化成工業株式会社 メキタジンの液状シロップ製剤
IT1251161B (it) * 1991-08-07 1995-05-04 Derivati ammonio quaternari di (-) e (+)-3-(10 h-fenotiazin-10-ilmetil)-l-azabiciclo (2.2.2.)ottano e composizioni farmaceutiche che li contengono
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
FR2822709B1 (fr) * 2001-03-30 2007-01-19 Antialis Composition pharmaceutique anti-allergique comprenant au moins un allergene et au moins un compose antihistaminique
DE10158036B4 (de) * 2001-11-27 2007-05-03 Kosmas Kg Antiallergisches Mittel und dessen Verwendung
WO2004066960A2 (fr) * 2003-01-28 2004-08-12 Schering Corporation Combinaison d'antagonistes des recepteurs h1, h3 et h4 en vue du traitement d'inflammations pulmonaires allergiques et non allergiques, de congestions et de rhinites allergiques
JP2005060233A (ja) * 2003-08-08 2005-03-10 Rohto Pharmaceut Co Ltd 皮膚外用剤
EP1526135A1 (fr) * 2003-10-24 2005-04-27 Warner-Lambert Company LLC Azabenzodiazepines utiles comme inhibiteurs de pde4
WO2005063253A1 (fr) * 2003-12-26 2005-07-14 Taiho Pharmaceutical Co., Ltd. Composition medicinale pour le traitement de symptomes allergiques
FR2896690B1 (fr) * 2006-01-30 2008-05-02 Pierre Fabre Medicament Sa Utilisation de l'enantiomere(s) de la mequitazine pour la preparation d'un medicament, tout en limitant la toxicite genomique

Also Published As

Publication number Publication date
TW200932242A (en) 2009-08-01
CN101883566A (zh) 2010-11-10
IL206073A0 (en) 2010-11-30
AR070673A1 (es) 2010-04-28
FR2924344B1 (fr) 2010-04-16
EP2255811A1 (fr) 2010-12-01
TN2010000241A1 (en) 2011-11-11
JP2011505411A (ja) 2011-02-24
KR20100108347A (ko) 2010-10-06
FR2924345B1 (fr) 2010-06-04
RU2510273C2 (ru) 2014-03-27
WO2009071625A1 (fr) 2009-06-11
CA2706898A1 (fr) 2009-06-11
MA31930B1 (fr) 2010-12-01
RU2010125711A (ru) 2012-01-10
NZ586212A (en) 2012-09-28
AU2008333220B2 (en) 2014-04-24
FR2924344A1 (fr) 2009-06-05
ZA201004312B (en) 2011-02-23
ZA201007626B (en) 2011-08-31
AU2008333220A1 (en) 2009-06-11
CL2008003584A1 (es) 2009-05-22
EP2227235A1 (fr) 2010-09-15
BRPI0820652A2 (pt) 2019-09-10
FR2924345A1 (fr) 2009-06-05
PA8805501A1 (es) 2009-12-16
JP2014065726A (ja) 2014-04-17
MX2010006139A (es) 2010-10-15
CN101883566B (zh) 2013-03-06
US20100273752A1 (en) 2010-10-28
EP2227235B1 (fr) 2014-11-12

Similar Documents

Publication Publication Date Title
WO2007018998A3 (fr) Benzimidazoles tricycliques et leur utilisation comme modulateurs du recepteur metabotropique du glutamate
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
WO2007112352A3 (fr) Utilisation d'analogues d'alcyne/ alcène de cyclosporine pour prévenir ou traiter des troubles d'origine virale
HK1120441A1 (en) Drugs for treatment of ovarian cancer
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
WO2005070930A3 (fr) Composes de tetrahydrocarboline comme agents anticancereux
IL201317A0 (en) Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
WO2008077557A8 (fr) Dérivés 8-éthynylxanthine en tant qu'antagonistes sélectifs du récepteur 2a
WO2006017188A3 (fr) Traitement adjuvant d’antipsychotiques atypiques à base de memantine dans des cas de schizophrénie
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
WO2007120690A3 (fr) Thérapie combinée avec des antagonistes des récepteurs histaminiques h1r et h4r pour le traitement du prurit
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
WO2007095389A3 (fr) traitement de maladies hyperprolifEratives avec la camptothecine n-oxyde et des analogues de celle-ci
WO2008092072A3 (fr) Modulateurs du récepteur métabotropique du glutamate de sous-type 5 et leurs utilisations
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
WO2007145863A3 (fr) Formulation à libération prolongée de naltréxone
HK1148667A1 (en) Mequitazine for treating or preventing pathologies involving histamine h4 receptors
TW200806321A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007098090A3 (fr) Traitement des maladies hyperprolifératives avec des n-oxydes de modulateurs des récepteurs d'œstrogènes
MX2008003230A (es) Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.
TW200833331A (en) Use of 10-[(3R)-1-azabicyclo [2,2,2] oct-3-ylmethyl]-10H-phenothiazine for the preparation of a medication exerting a selective inhibition of the M1, M2 and M3 muscarinic receptors
WO2008016665A3 (fr) Composés et méthodes de traitement de troubles médiés par flt3
WO2006076569A3 (fr) Heterocycles bicycliques servant de modulateurs aux recepteurs cannabinoides
WO2011094208A3 (fr) Procédés et compositions pharmaceutiques pour la prévention et le traitement d'une insuffisance rénale

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161204